InterContinental Hotels Group PLC (IHG) remains a strong Buy due to continued growth in revenue per available room (RevPAR), a robust pipeline, and strategic expansion in the luxury hotel segment. The company’s opportunity in Japan is notable, with about 30% room growth driven by premium hotel development and increasing demand from Western and high-end tourists. Fee revenue is expected to grow in the high single digits, with adjusted earnings per share (EPS) projected to grow at a compound annual rate of 12-15%. IHG’s stock currently trades at a discount compared to peers, with a justified price target of around $180 per share, implying an upside of approximately 11% as valuation normalizes.
InterContinental Hotels Group's strategic expansion in Japan is noted alongside Pluang's Consumer Cyclical sector data. For readers following this sector, here is Pluang's market snapshot as of Sep 30, 2026 02:02 WIB: out of 112 priced US stocks, 51 rose and 61 fell. Notable movers include NIO at USD 3.42 with a 1-day change of -4.87% and typical hold time of 81 days, XPEV at USD 9.47 down 4.77% with 80 days hold, and Norwegian Cruise Line Holdings (NCLH) at USD 14.94 up 4.40% with 68 days hold time and 91% buy order activity.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
